Have you heard the latest in HPV Testing?

The Latest Advances in Cervical Cancer Screening and Management:
Performance and Genotyping Results from the BD Onclarity™ HPV Assay US Clinical Trial

Online registration for this event has ended.
Registration will be available onsite at the event on a first-come, first-serve basis. 
  • Where

    ASCCP 2018 Annual Meeting | Red Rock Casino Resort & Spa
    11011 W Charleston Blvd Las Vegas, NV 89135
    Industry-Supported Scientific Symposium
  • WHEN

    Thursday April 19 | 12:00 - 1:30 pm
    Seating is limited. Be sure to arrive early to secure your spot!
    Lunch will be served.
  • Course Description

    What are the latest advances in HPV and cervical cancer screening that could improve outcomes for your patients? Find out when you join noted experts Mark H. Stoler, MD, and Thomas C. Wright, Jr., MD, at ASCCP 2018. They will review the data and results from the BD Onclarity™ US clinical trial - a prospective, multi-center clinical trial that included more than 33,500 US women. The presentations will cover performance by intended use, including ASCUS triage, co-testing, primary screening, and results in vaccinated and unvaccinated cohorts. Discover how this new HPV diagnostic test will provide clinicians with another choice in detecting and genotyping high-risk HPV virus infection.  


    - BD Onclarity™ US Clinical Trial Overview
    - Performance by Intended Use: ASCUS triage, Co-testing and Primary Screening 
    - Results in the Vaccinated vs. Unvaccinated Cohorts

    This promotional educational activity is brought to you by BD Life Sciences and the information must be presented in compliance with FDA requirements applicable to BD Life Sciences. Pursuant to the Open Payments Act, your name, the value and the purpose of any meal or other items you receive will be reported and this information will be publicly accessible.

    By submitting this form, you confirm understanding that by consuming the meal provided at this symposium, the value of the meal will be reportable pursuant to the Open Payments Act.

Section 2: Spin Straw into Gold